Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAFFODIL: Phase 3 nipocalimab in adults with moderate to severe Sjogren's disease
jRCT2071240089Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in Sjögren's syndrome comparing Nipocalimab SC + standard of care with Placebo SC + standard of care (2 arms). Primary endpoint: Change from baseline in ClinESSDAI score at Week 48. Started Mar 2025; status: active, not recruiting.
02
Drugs
nipocalimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on jRCT2071240089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240089.